Castle Creek Biosciences
Exton, US · Founded 2018 · Delaware corporation · 4 known investors
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
Founders & leadership
MG
Matthew GantzPresident and Chief Executive Officer
DC
David Chu
MT
Michael Townsley
CJ
Christopher J. Larson
RW
Rhea Williams
JS
Jude SullivanExecutive Officer
DP
Darien ParhadExecutive Officer
MD
Michael DerbyChief Executive Officer
TC
Timothy CunniffDirector
MC
Matthew CrabtreeDirector
DB
David BrillDirector
JA
Jeffrey AroninDirector
Investors · 4
Competitors · 6
by search overlapPatSnap56 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Concord Communications50 shared keywords
Cowles_Investments_StemCentrx49 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Mapquest46 shared keywordsProvider of geographical information systems and services; acquired by America Online.
Aro Biotherapeutics39 shared keywords
BBB33 shared keywords
Companies competing with Castle Creek Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$75MraisedFeb 2025 · 30 investors · BiotechnologyRule 506(b)
▶$75MraisedFeb 2025 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BrillDirector
- Matthew CrabtreeDirector
- Jeffrey AroninDirector
- Matthew GantzExecutive Officer, Director
- Patrick MorrisDirector
- Jude SullivanExecutive Officer
- Darien ParhadExecutive Officer
- Antonio GraciasDirector
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $2.8M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$112.8MraisedMay 2022 · 54 investors · BiotechnologyRule 506(b)
▶$112.8MraisedMay 2022 · 54 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark GrafDirector
- Matthew J. GantzExecutive Officer, Director
- W. Bradford MiddlekauffExecutive Officer
- Mary SpellmanExecutive Officer
- Jeffrey S. AroninDirector
- Patrick J. MorrisDirector
- Antonio GraciasDirector
- Offering amount
- $112.8M
- Amount sold
- $112.8M
- Sales commissions
- $1.7M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$11.8MraisedFeb 2022 · 6 investors · BiotechnologyRule 506(b)
▶$11.8MraisedFeb 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. AroninDirector
- W. Bradford MiddlekauffExecutive Officer
- Matthew J. GantzExecutive Officer, Director
- Mark GrafDirector
- Patrick J. MorrisDirector
- Antonio GraciasDirector
- Babar GhiasExecutive Officer
- Mary SpellmanExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- Sales commissions
- $625K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25MraisedJul 2021 · 36 investors · BiotechnologyRule 506(b)
▶$25MraisedJul 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew J. GantzExecutive Officer, Director
- Mary SpellmanExecutive Officer
- Gregory MacMichaelExecutive Officer
- Gregory WujekExecutive Officer
- Antonio GraciasDirector
- W. Bradford MiddlekauffExecutive Officer
- Patrick J. MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Sales commissions
- $625K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$54.6MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$54.6MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. AroninDirector
- Gregory WujekExecutive Officer, Director
- Patrick J. MorrisExecutive Officer, Director
- Timothy M. CunniffDirector
- Antonio J. GraciasDirector
- Offering amount
- $54.6M
- Amount sold
- $54.6M
- Minimum investment
- $82.4K
- Sales commissions
- $710K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$560.5MraisedOct 2018 · 19 investors · PharmaceuticalsRule 506(b)
▶$560.5MraisedOct 2018 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey AroninDirector
- Michael DerbyExecutive Officer, Director
- Antonio GraciasDirector
- Patrick MorrisExecutive Officer, Director
- Timothy CunniffDirector
- Offering amount
- $560.5M
- Amount sold
- $560.5M
- Sales commissions
- $1.2M
- Placement agents
- Octagon Capital Group, LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciencesglobenewswire.com · 2025
- Castle Creek Biosciences raises US $112.8 million - Cure EBcure-eb.org · 2022
- Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipelineparagonbiosci.com · 2022
- Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseasesglobenewswire.com · 2020
- Castle Creek Biosciences Raises $75M in Funding - FinSMEsfinsmes.com · 2020